These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 21807761)

  • 1. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
    N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy.
    Zhumkhawala AA; Gleason JM; Cheetham TC; Niu F; Loo RK; Dell RM; Jacobsen SJ; Chien GW
    Urology; 2013 May; 81(5):1010-5. PubMed ID: 23490521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.
    James H; Aleksic I; Bienz MN; Pieczonka C; Iannotta P; Albala D; Mariados N; Mouraviev V; Saad F
    Urology; 2014 Jul; 84(1):164-8. PubMed ID: 24976229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.
    Tanvetyanon T
    Cancer; 2005 Jan; 103(2):237-41. PubMed ID: 15597384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fracture risk in androgen deprivation therapy: a Canadian population based analysis.
    Lau YK; Lee E; Prior HJ; Lix LM; Metge CJ; Leslie WD
    Can J Urol; 2009 Dec; 16(6):4908-14. PubMed ID: 20003666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone health care for patients with prostate cancer receiving androgen deprivation therapy.
    Tsang DS; Alibhai SM
    Hosp Pract (1995); 2014 Apr; 42(2):89-102. PubMed ID: 24769788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer.
    Nadler M; Alibhai S; Catton P; Catton C; To MJ; Jones JM
    BJU Int; 2013 Jun; 111(8):1301-9. PubMed ID: 23351062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Androgen deprivation therapy for prostate cancer and osteoporotic risk].
    Cortet B; Lartigau E; Caty A; Moulinier F; Staerman F; Villamizar-Vesga J; Villers A
    Prog Urol; 2012 Sep; 22 Suppl 2():S31-8. PubMed ID: 23098788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.